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Abstract
Purpose Observational studies suggest that dietary and serum calcium are risk factors for prostate cancer. However, such 
studies suffer from residual confounding (due to unmeasured or imprecisely measured confounders), undermining causal 
inference. Mendelian randomization uses randomly assigned (hence unconfounded and pre-disease onset) germline genetic 
variation to proxy for phenotypes and strengthen causal inference in observational studies. We tested the hypothesis that 
serum calcium is associated with an increased risk of overall and advanced prostate cancer.
Methods A genetic instrument was constructed using five single-nucleotide polymorphisms robustly associated with serum 
calcium in a genome-wide association study (n ≤ 61,079). This instrument was then used to test the effect of a 0.5 mg/dL 
increase (1 standard deviation, SD) in serum calcium on risk of prostate cancer in 72,729 men in the PRACTICAL (Prostate 
Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) Consortium (44,825 cases, 27,904 
controls) and risk of advanced prostate cancer in 33,498 men (6,263 cases, 27,235 controls).
Results We found weak evidence for a protective effect of serum calcium on prostate cancer risk (odds ratio [OR] per 0.5 mg/
dL increase in calcium: 0.83, 95% CI 0.63–1.08; p = 0.12). We did not find strong evidence for an effect of serum calcium 
on advanced prostate cancer (OR per 0.5 mg/dL increase in calcium: 0.98, 95% CI 0.57–1.70; p = 0.93).
Conclusions Our Mendelian randomization analysis does not support the hypothesis that serum calcium increases risk of 
overall or advanced prostate cancer.
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Introduction
Prostate cancer is the most frequently diagnosed cancer 
among men globally and is a common cause of male cancer 
death [1]. Despite the considerable global burden attributed 
to prostate cancer, to date few risk factors (advanced age, 
ethnicity, family history of prostate cancer) have been identi-
fied and no modifiable risk factors have been established for 
this condition [2]. Nonetheless, global variation in prostate 
cancer mortality [3, 4] and findings from migration studies 
(i.e. the convergence toward local prostate cancer mortality 
rates among men who migrate from non-Western to Western 
populations) [5–7] provide support for a role of modifiable 
risk in prostate carcinogenesis.
Dietary calcium intake has been associated with an 
increased risk of prostate cancer in prospective epidemio-
logical studies [8–10]. In a meta-analysis of fifteen prospec-
tive studies, high dietary calcium intake, as compared to 
low intake, was associated with an 18% (95% CI 8–30%) 
increased prostate cancer risk [11]. Similarly, high calcium 
intake has been linked to an increased risk of advanced 
[12–14] and fatal prostate cancer [13], though findings have 
been inconsistent [15, 16]. Though serum calcium is nor-
mally tightly regulated in the body and does not fluctuate 
substantially across levels of dietary calcium intake [17, 18], 
Giovannucci proposed that higher dietary calcium may influ-
ence risk of prostate cancer by lowering circulating levels 
of 1,25(OH)2 vitamin D, a presumed tumour suppressor, 
[19–21] in order to achieve calcium homeostasis [22]. A 
more direct method of testing the hypothesis that calcium 
metabolism influences prostate carcinogenesis would be to 
examine the association of serum calcium levels with pros-
tate cancer risk. However, studies examining the association 
of pre-diagnostic serum calcium levels with incident or fatal 
prostate cancer [23, 24], or post-diagnostic serum calcium 
with prostate cancer survival [25, 26], have generated con-
flicting results: some report positive associations of serum 
calcium with prostate cancer [23, 26, 27], whereas others 
have been compatible with a null effect [23–25, 28, 29].
Establishing a causal role of elevated serum calcium in 
prostate carcinogenesis could have therapeutic implications 
for the prevention or treatment of prostate cancer. However, 
obtaining reliable estimates of causal effects from obser-
vational studies is a challenge as these studies are prone 
to various biases including residual confounding (due to 
unmeasured or imprecisely measured confounders) and 
exposure measurement error which can undermine robust 
causal inference [30, 31].
Mendelian randomization (MR) is an analytical approach 
that uses randomly assigned (hence unconfounded and 
pre-disease) germline genetic variants as instruments (i.e. 
proxies for the risk factor of interest) to examine the causal 
effects of risk factors on health outcomes [32, 33]. MR is a 
form of instrumental variable (IV) analysis that allows for 
unbiased causal effects to be estimated if three assumptions 
are met: (1) the instrument (e.g. a single germline genetic 
variant or a multi-allelic score) is robustly associated with 
the exposure of interest; (2) the instrument is not associ-
ated with any confounding factor(s) that would otherwise 
distort the association between the exposure and outcome; 
and (3) there is no pathway through which an instrument 
influences an outcome except through the exposure (known 
as the “exclusion restriction criterion”). The random alloca-
tion of genetic variants at conception and the independent 
assortment of parental alleles at meiosis means that, at a 
population level, analyses using genetic variants as instru-
ments for a risk factor of interest should not be confounded 
by environmental and lifestyle factors that typically distort 
observational studies.
The availability of germline genetic variants (SNPs—
single-nucleotide polymorphisms) robustly associated with 
serum calcium and prostate cancer in separate and independ-
ent genome-wide association studies (GWAS) [34, 35] can 
permit examination of the causal effect of increased serum 
calcium on prostate cancer risk using a “two-sample Mende-
lian randomization” framework [36]. Such an approach pro-
vides an efficient and statistically robust method of apprais-
ing causal relationships between traits, bypassing the need 
to have access to complete phenotypic and genotypic data 
on all participants in one sample.
Given uncertainty surrounding the role of serum calcium 
in prostate cancer aetiology and progression, we used data 
from: (i) a GWAS of serum calcium in up to 61,079 individ-
uals of European descent; and (ii) a GWAS of prostate can-
cer in men of European descent (n = 72,729). These samples 
were used to perform a two-sample Mendelian randomiza-
tion analysis to examine the causal effect of elevated serum 
calcium with risk of overall and advanced prostate cancer.
Materials and methods
Prostate cancer population
We obtained summary genome-wide association study 
(GWAS) statistics from analyses on 44,825 men with pros-
tate cancer and 27,904 control men of European descent 
from 108 studies in the Prostate Cancer Association Group 
to Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium [35]. Summary statistics were 
also obtained from analyses on 6,263 men with advanced 
prostate cancer (defined as Gleason score ≥ 8, prostate-spe-
cific antigen > 100 ng/mL, metastatic disease (M1), or death 
from prostate cancer) and 27,235 controls. All studies in 
PRACTICAL have the relevant Institutional Review Board 
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approval from each country, in accordance with the Decla-
ration of Helsinki. Genotype data were obtained by either 
direct genotyping using an Illumina Custom Infinium array 
(OncoArray) consisting of approximately 530,000 SNPs [37] 
or by imputation with reference to the 1000 Genomes Pro-
ject Phase Three dataset [38]. All SNPs with a poor imputa-
tion quality (r2 < 0.30), a minor allele frequency of < 1%, a 
call rate of < 98%, or evidence of violation of Hardy–Wein-
berg equilibrium (p < 10−7 in controls or p < 10−12 in cases) 
were removed. Analyses were performed across individual 
studies in PRACTICAL using logistic regression in models 
that were adjusted for the first seven principal components of 
ancestry (to control for population stratification) and study 
relevant covariates. Results were meta-analysed across the 
PRACTICAL studies using an inverse-variance fixed-effects 
approach to give an overall effect-estimate.
Calcium‑associated SNP selection
SNPs to proxy for serum calcium were obtained from a 
GWAS meta-analysis of 39,400 individuals of European 
descent from 17 population-based cohorts [34]. Genetic 
instruments were constructed by obtaining SNPs shown 
to robustly (p < 1 × 10−7) and independently to associate 
(r2 < 0.01) with serum calcium levels that were replicated 
(one-sided p < 0.05) in an independent meta-analysis of 
up to 21,679 individuals of European descent. In total, 
seven SNPs located in or near CASR (rs1801725), DGKD 
(rs1550532), GCKR (rs780094), GATA3 (rs10491003), 
CARS (rs7481584), DGKH (rs7336933), and CYP24A1 
(rs1570669) were independently replicated. Summary 
data on rs1801725 were not available in the PRACTICAL 
OncoArray analysis so we used a proxy SNP located in 
CASR (rs17251221) in high linkage disequilibrium with 
rs1801725 (r2 = 0.85), using the 1000 Genomes Project CEU 
database as a reference [39]. As an initial test for horizontal 
pleiotropy (a single locus influencing multiple phenotypes 
through independent biological pathways; a violation of the 
“exclusion restriction criterion”), we examined associations 
of calcium SNPs with thousands of other traits in a large cat-
alogue of summary genetic association statistics from previ-
ously published GWAS (MR-Base; http://www.mrbas e.org) 
[40]. After applying a Bonferroni correction to account for 
multiple “look ups” of phenotypic traits with all 7 SNPs 
examined (p < 0.05/x, where x represents the number of phe-
notypic trait “look ups” performed; 859 to 1,060 look-ups 
performed with corresponding corrected p value thresholds: 
5.8 × 10−5 to 4.7 × 10−5 across seven SNPs), we identified 
two SNPs (rs780094, rs1550532) that associated with mul-
tiple traits in MR-Base. rs780094 was robustly associated 
(p < 4.8 × 10−5) with various measures of lipids, insulin, and 
anthropometric traits and rs1550532 was robustly associ-
ated (p < 4.8 × 10−5) with inflammatory bowel disease; these 
traits have all been hypothesized to influence prostate cancer 
risk [41–44]. Additionally, rs1550532 was strongly associ-
ated with levels of multiple “unknown metabolites” from 
untargeted GWAS of metabolomic studies [45]. Given that 
these two SNPs could influence prostate cancer risk through 
biological pathways independent of calcium (i.e. horizon-
tal pleiotropy), we removed them from our genetic instru-
ment. Consequently, our genetic instrument for calcium used 
five SNPs that we assessed as being exclusively associated 
with serum calcium (rs17251221, rs10491003, rs7481584, 
rs7336933, rs1570669).
Statistical analysis
We generated estimates of the proportion of variance in 
serum calcium for our genetic instrument (R2) and F-statis-
tics to examine the strength of our instruments and to test 
for weak instrument bias (a reduction in statistical power 
to reject the null hypothesis when an instrument explains 
only a small proportion of variance in an exposure), using 
methods previously described [46]. Power calculations were 
performed using previously reported methods [47] to deter-
mine whether we had sufficient sample size to identify effect 
sizes in our MR analyses that were of a similar magnitude to 
those reported in the observational literature.
We first examined the effect of serum calcium on over-
all and advanced prostate cancer for individual SNPs, using 
the Wald ratio to generate beta-coefficients, and the delta 
method approximation of the standard error. SNPs were then 
combined into a multi-allelic genetic instrument (to increase 
the variance explained in serum calcium) and the causal 
effect of this instrument on overall and advanced prostate 
cancer was examined using a maximum likelihood-based 
approach [48]. For both individual-SNP and multi-allelic 
instrument analyses, the effect of serum calcium on pros-
tate cancer was scaled to represent a 0.5 mg/dL increase 
(~ 1 SD). I2 statistics were calculated to determine the per-
centage of heterogeneity across SNPs in causal estimates 
due to variability beyond chance and Cochran’s Q test was 
used to test homogeneity across SNPs in causal estimates 
[49]. Maximum-likelihood estimates were then generated 
using fixed-effects or random-effects models depending 
on heterogeneity of causal effect estimates across SNPs in 
multi-allelic instruments. p values were generated using a 
t-distribution with N − 1 degrees of freedom where N is the 
number of SNPs utilized in the instrument.
To examine the presence of directional pleiotropy (where 
the horizontally pleiotropic effect across a genetic instru-
ment do not average to zero) from unmeasured traits, we 
performed two sensitivity analyses: MR-Egger regression 
[50] and the weighted median estimator approach [51]. MR-
Egger relaxes the exclusion restriction criterion and thus can 
provide unbiased estimates of causal effects even when all 
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IVs in an instrument are invalid through violation of this 
assumption. This approach performs a weighted general-
ized linear regression of the SNP-outcome coefficients on 
the SNP-exposure coefficients with an unconstrained inter-
cept term. Provided that the InSIDE (Instrument Strength 
Independent of Direct Effect) assumption is met (that no 
association exists between the strength of gene-exposure 
associations and the strength of bias due to horizontal plei-
otropy) and that measurement error in the genetic instrument 
is negligible (“No Measurement Error” or NOME assump-
tion) [52], the slope generated from MR-Egger regression 
can provide an estimate of the causal effect of calcium on 
prostate cancer that is adjusted for directional pleiotropy 
and the intercept term can provide a formal statistical test 
for directional pleiotropy. To test NOME, we generated 
weighted I2GX values for overall and advanced prostate 
cancer analyses to quantify the expected dilution of MR-
Egger estimates due to NOME violations [52]. The weighted 
median estimator (WME) approach provides an estimate of 
the weighted median of a distribution in which individual IV 
causal estimates in an instrument are ordered and weighted 
by the inverse of their variance. Unlike MR-Egger which 
can provide an unbiased causal effect even when all IVs 
are invalid, WME requires that at least 50% of the informa-
tion in a multi-allelic instrument is coming from SNPs that 
are valid IVs in order to provide an unbiased estimate of a 
causal effect in an MR analysis. However, the WME has 
two advantages over MR-Egger in that it provides improved 
precision as compared to the latter and does not rely on the 
InSIDE assumption.
We also performed a leave-one-out permutation analysis 
to examine whether any of our results were driven by any 
individual SNP from our multi-allelic instrument.
All statistical analyses were performed using R version 
3.3.1.
Results
Our genetic instrument explained 0.71% of variance in 
serum calcium levels. The corresponding F-statistic for our 
instrument (86.2) suggested that our instrument was unlikely 
to suffer from weak instrument bias [53]. Power calculations 
suggested that we would have 80% power to detect an OR of 
at least 1.25 (or, conversely a protective OR of at least 0.80) 
per 0.5 mg/dL increase in serum calcium on overall pros-
tate cancer risk at an alpha level (false positive) of 5%. For 
advanced prostate cancer, we had 80% power to detect an 
OR of at least 1.81 (or a protective OR at least 0.55), which 
would be of similar magnitude to effect estimates reported 
in the largest observational study of fatal prostate cancer 
to date (HR [Hazard Ratio] 1.66 per 0.5 mg/dL increase in 
serum calcium) [26].
Estimates of causal effects of individual calcium SNPs 
per 0.5 mg/dL increase in serum calcium on overall and 
advanced prostate cancer are presented in Table 1. Individu-
ally, there was little evidence that any of the five SNPs were 
causally associated with overall or advanced prostate cancer.
Overall prostate cancer
In an MR analysis combining the five serum calcium-related 
SNPs into a multi-allelic genetic instrument, there was weak 
evidence of a protective effect of serum calcium on prostate 
cancer risk (OR per 0.5 mg/dL increase in calcium: 0.83, 
95% CI 0.63–1.08; p = 0.12) (Table 2). Effect estimates were 
similar using the weighted median estimator (OR 0.80, 95% 
CI 0.58–1.12) and MR-Egger (OR 0.87, 95% CI 0.46–1.64). 
The MR-Egger intercept parameter did not suggest evidence 
of directional pleiotropy (OR 1.00, p = 0.76).
Table 1  Descriptive statistics of calcium SNPs and estimates of their causal effects on overall and advanced prostate cancer in PRACTICAL
EA reflects the allele that increases serum calcium levels. OR (95% CI) represents the exponential increase in odds for each 0.5 mg/dL increase 
in serum calcium
Chr chromosome, EA effect allele, NEA non-effect allele, OR odds ratio, 95% CI 95% confidence interval
SNP Chr Gene(s) EA NEA Overall prostate can-
cer OR (95% CI)
p value Advanced prostate 
cancer OR (95% CI)
p value
rs17251221 3 CASR G A 0.84 (0.65–1.09) 0.18 0.83 (0.51–1.35) 0.45
rs10491003 10 GATA3 T C 0.56 (0.28–1.15) 0.12 1.58 (0.42–5.93) 0.50
rs7481584 11 CARS G A 0.72 (0.37–1.40) 0.33 1.21 (0.34–4.23) 0.77
rs7336933 13 DGKH; KIAA0564 G A 1.36 (0.68–2.70) 0.39 1.60 (0.44–5.80) 0.48
rs1570669 20 CYP24A1 G A 0.66 (0.35–1.25) 0.20 1.01 (0.31–3.29) 0.99
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Advanced prostate cancer
MR analyses found little evidence for an effect of serum cal-
cium on advanced prostate cancer risk (0.5 mg/dL calcium 
increase: OR 0.98, 95% CI 0.57–1.70; p = 0.93) (Table 2). 
Sensitivity analyses to examine directional pleiotropy were 
consistent with a null effect of serum calcium on advanced 
prostate cancer.
Calculation of the I2GX statistic suggested little attenua-
tion of our MR-Egger estimates due to measurement error 
for both overall prostate cancer (I2GX = 0.89) and advanced 
prostate cancer (I2GX = 0.91), so adjustment of MR-Egger 
estimates to account for mild dilution bias was not per-
formed [52]. Leave-one-out permutation analyses for over-
all and advanced prostate cancer did not find evidence that 
the effect estimate based on the multi-allelic instrument was 
being driven by any single serum calcium-related SNP (Sup-
plementary Table 1).
Discussion
Our Mendelian randomization analysis does not support the 
hypothesis that serum calcium increases the risk of overall or 
advanced prostate cancer. Indeed, the point estimates were 
in the opposite direction (though imprecisely estimated) to 
findings from some observational studies.
Our findings are not consistent with some laboratory stud-
ies which have reported a role of calcium in promoting loss 
of differentiation and increased proliferation of prostate can-
cer cells [54, 55]. Prospective studies that have examined the 
association of serum calcium with incident prostate cancer 
have generated conflicting findings: three did not find strong 
evidence for an association (HR for upper vs lower tertile: 
1.31, 95% CI 0.77–2.20 [23]; OR for upper vs lower quar-
tile: 1.04, 95% CI 0.78–1.39 [28]; HR per quartile increase: 
0.99, 95% CI 0.94–1.03 [29]), whereas one reported a weak 
inverse association between calcium and prostate cancer (HR 
per SD increase: 0.97, 95% CI 0.85–1.00) [24]. Likewise, 
some studies that have examined an association between 
serum calcium and fatal prostate cancer have reported posi-
tive risk relationships (HR for upper vs lower tertile: 2.07, 
95% CI 1.06–4.04 [27]; HR for upper vs lower tertile: 2.68, 
95% CI 1.02–6.99 [23]; HR per 0.1 mmol/L increase: 1.50, 
95% CI 1.04–2.17 [26]) whereas others have not found 
strong evidence of an association (HR per 1-SD increase: 
1.00, 95% CI 0.92–1.09 [24]; HR for upper vs lower quartile: 
0.75, 95% CI 0.49–1.15 [25]). It is plausible that discord-
ance between previously reported observational findings and 
our MR analysis may reflect residual confounding in the 
former (e.g. through other dietary, lifestyle, or molecular 
factors). It is also possible that studies reporting associa-
tions of dairy products with subsequent prostate cancer risk 
may reflect the mediating role of proteins and growth factors 
(e.g. insulin-like growth factor 1) in prostate carcinogenesis, 
and not calcium per se [11, 56, 57]. Nevertheless, the weak 
evidence that we found for a potential protective effect of 
serum calcium on overall prostate cancer is consistent with 
a meta-analysis of four randomized controlled trials that 
reported that daily calcium supplementation (≥ 500 mg/day) 
reduced prostate cancer risk (RR [Risk Ratio] 0.54, 95% CI 
0.30–0.96, p = 0.03), though this analysis was only based on 
48 men with prostate cancer (3,297 and 3,248 in the inter-
vention and control groups, respectively) [58].
Strengths of our analysis include the use of a Mende-
lian randomization approach to appraise the relationship 
of serum calcium with prostate cancer risk which should 
help to minimize or avoid confounding through lifestyle or 
environmental factors that may have biased findings from 
previous observational analyses. Further, given the time 
required for nutritional biomarkers to influence carcinogen-
esis [59] and the considerable latency period of prostate can-
cer [60], the use of germline genetic variation as an instru-
ment should allow for sufficient time to confer an effect on 
Table 2  Mendelian 
randomization derived causal 
effects of a 0.5 mg/dL increase 
in serum calcium on overall and 
advanced prostate cancer using 
a multi-allelic instrument in 
PRACTICAL
a Odds ratio [OR] (95% confidence interval, CI) represents the exponential increase in odds for each 
0.5 mg/dL increase in serum calcium
b Maximum likelihood estimate obtained using a fixed-effects model (I2 = 0%, Qp = 0.44)




















0.98 (0.57–1.70) 0.92 (0.50–1.66) 0.72 (0.24–2.15) 0.42
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prostate cancer. This is because MR will estimate the effect 
of life-long exposure to elevated serum calcium on pros-
tate cancer risk. MR will also offer an additional strength 
over prospective studies of dietary or serum calcium which 
can suffer from substantial (albeit, likely non-differential) 
measurement error: measurement error in genetic studies 
is often low as modern genotyping technologies provide 
relatively precise measurement of genetic variants [61]. 
While residual measurement error in SNP-exposure esti-
mates cannot be ruled out, such non-differential measure-
ment error would likely bias associations toward the null, 
providing a conservative effect estimate. The use of a two-
sample MR approach allowed us to utilize summary effect 
estimates from two large GWAS and thus increase statisti-
cal power in our analyses. Though the F-statistic generated 
for our instrument suggested that weak instrument bias was 
unlikely, in a two-sample MR setting, weak instrument bias 
if present would be expected to lead to an attenuated effect 
estimate. This is in contrast to a one-sample MR analysis in 
which weak instrument bias will tend to bias effect estimates 
toward the confounded observational study estimate [36]. 
Lastly, by obtaining summary effect estimates for both expo-
sure and outcome datasets from GWAS that were restricted 
to individuals of European descent and adjusted for prin-
cipal components of ancestry, we reduced (though did not 
eliminate) the possibility of confounding through population 
stratification in our MR analyses (though this may limit gen-
eralizability of our findings to other ethnicities).
There are limitations to our analysis. First, given the 
composite characterization of advanced prostate cancer in 
the summary GWAS data that we obtained (Gleason ≥ 8, 
prostate-specific antigen > 100 ng/mL, metastatic disease 
(M1), or death from prostate cancer), it is difficult to directly 
compare our findings with those from prospective studies 
that examined associations between calcium and fatal pros-
tate cancer. Second, though our MR analysis for advanced 
prostate cancer was sufficiently powered to detect effect 
sizes compatible with those reported in the observational 
literature, it was not powered to detect effect sizes of a more 
modest magnitude. Further identification of independent 
genetic variants that influence serum calcium (increasing 
instrument strength further by explaining a larger propor-
tion of the variance in serum calcium) in addition to larger 
GWAS of advanced prostate cancer will help to improve 
statistical power for future analyses. A final limitation of 
our analysis was that we were unable to examine possible 
non-linear effects of serum calcium on prostate cancer using 
summarized genetic data, which have been proposed previ-
ously [8].
Given that our findings raise the possibility that serum 
calcium may be protective against prostate cancer, there is 
a need to follow-up these results in large and independent 
datasets. Further identification of additional independent 
genetic variants robustly associated with serum calcium will 
help to improve precision of future analyses.
In conclusion, our Mendelian randomization analysis 
does not support the hypothesis that serum calcium increases 
the risk of overall or advanced prostate cancer.
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